TP53 and myelodysplastic syndrome: However, a phase III study (NCT03745716) has also compared eprenetapopt plus azacitidine with azacitidine alone in the treatment of patients with myelodysplastic syndrome (MDS), and the coexisting TP53 mutation failed to meet its primary endpoint concerning CR rate.